{
    "clinical_study": {
        "@rank": "89184", 
        "arm_group": {
            "arm_group_label": "Ruxolitinib", 
            "arm_group_type": "Experimental", 
            "description": "All patients will recieve ruxolitinib"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after\n      treatment interruption due to loss of response and/or adverse events."
        }, 
        "brief_title": "A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Myelofibrosis", 
        "condition_browse": {
            "mesh_term": "Primary Myelofibrosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status\n             according to the 2008 revised International Standard Criteria\n\n          -  Peripheral blast count < 10%\n\n          -  Requires therapy for MF in the opinion of the investigator\n\n          -  Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive\n             weeks and experienced treatment interruption because of lossof response or adverse\n             event\n\n          -  Patients adhering to the Screening phase assessments and undergoing a a\n             ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks\n\n          -  ECOG performance status 0, 1, 2, or 3\n\n          -  Adequate bone marrow function\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients not initially responding (primary resistance) to ruxolitinib therapy\n\n          -  Patients who underwent a splenectomy or spleen radiation\n\n          -  Patients currently scheduled for bone marrow transplant\n\n          -  Patients who have discontinued ruxolitinib < 14 days prior to screening\n\n          -  Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg\n             total daily dose\n\n          -  Leukemic transformation\n\n          -  Inadequate renal function\n\n          -  Presence of clinically meaningful active bacterial, fungal, parasitic or viral\n             infection which requires therapy\n\n          -  Previous history of Progressive Multifocal Leuko-encephalopathy (PML)\n\n          -  Clinically significant cardiac disease or significant concurrent medical condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091752", 
            "org_study_id": "CINC424A2407"
        }, 
        "intervention": {
            "arm_group_label": "Ruxolitinib", 
            "description": "All patients will recieve ruxolitinib", 
            "intervention_name": "Ruxolitinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary Myelofibrosis", 
            "Hematologic Diseases", 
            "Myeloproliferative Disorders", 
            "INC424", 
            "Ruxolitinib"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria", 
                        "zip": "6020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "68305"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO", 
                        "zip": "40138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "FI", 
                        "zip": "50134"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Calabria", 
                        "country": "Italy", 
                        "state": "RC", 
                        "zip": "89124"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00161"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terni", 
                        "country": "Italy", 
                        "state": "TR", 
                        "zip": "05100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "41013"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "state": "Castilla y Leon", 
                        "zip": "37007"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08916"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "03010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadanonda", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28220"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Suspended"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Sebastian", 
                        "country": "Spain", 
                        "state": "Pais Vasco", 
                        "zip": "20014"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Canada", 
                "Germany", 
                "Italy", 
                "Spain", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: AGES (Bundesamt f\u00fcr Sicherheit im Gesundheitswesen)", 
                "Brazil: ANVISA - Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria", 
                "Canada: Health Canada", 
                "Germany: BfArM (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte)", 
                "Greece: National Organization of Medicines", 
                "Italy: AIFA (Agenzia Italiana del Farmaco)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Thailand: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients achieving \u226520% reduction from baseline in spleen volume by Week 24 after re-treatment with ruxolitinib", 
            "measure": "The effect of re-treatment with ruxolitinib on reduction in spleen volume of at least 20% from baseline, by Week 24", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091752"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients achieving \u226535% reduction from baseline in spleen volume by Week 24 after re-treatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on reduction in spleen volume of at least 35% from baseline, by Week 24", 
                "safety_issue": "No", 
                "time_frame": "By Week 24"
            }, 
            {
                "description": "Proportion of patients achieving \u226525% and \u226550% reduction respectively, from baseline, in spleen length by Week 24 after re-treatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on reduction in spleen length of at least 25% and 50% respectively, from baseline, by Week 24", 
                "safety_issue": "No", 
                "time_frame": "By Week 24"
            }, 
            {
                "description": "Change in spleen length as well as in spleen volume from baseline to each visit where measured after re-treatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on reduction in spleen volume and length over time", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "description": "Safety will be assessed by monitoring the frequency, duration and severity of Adverse Events, and evaluating changes in vital signs, electrocardiograms (ECGs), serum chemistry, hematology and urinalysis results.", 
                "measure": "The safety after re-treatment with ruxolitinib", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "description": "Proportion of patients achieving \u226525% and \u226550% reduction respectively, from baseline in total symptom score (MPN-SAF TSS) by Week 24 after re-treatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on reduction in MPN-SAF TSS of at least 25% and 50% respectively, from baseline, by Week 24", 
                "safety_issue": "No", 
                "time_frame": "By Week 24"
            }, 
            {
                "description": "Change in MPN-SAF TSS from baseline to each visit where measured after re-treatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on reduction in MPN-SAF TSS over time", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "description": "PGIC at each visit where measured after retreatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on Patient Global Impression of Change (PGIC)", 
                "safety_issue": "No", 
                "time_frame": "By Week 1 to Week 24"
            }, 
            {
                "description": "Change in EORTC QLQ-C30 and EQ-5 D-5L scores from baseline to each visit where measured after re-treatment with ruxolitinib", 
                "measure": "The effect of re-treatment with ruxolitinib on EORTC QLQ-C30 and EQ-5D-5L", 
                "safety_issue": "No", 
                "time_frame": "At Day 1, Week 8, Week 12, Week 16, Week 24"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}